# Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

> **NCT04662255** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Loxo Oncology, Inc.** · enrollment: 500 (estimated)

## Conditions studied

- Lymphoma, Mantle-Cell

## Interventions

- **DRUG:** Pirtobrutinib
- **DRUG:** Ibrutinib
- **DRUG:** Acalabrutinib
- **DRUG:** Zanubrutinib

## Key facts

- **NCT ID:** NCT04662255
- **Lead sponsor:** Loxo Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-04-08
- **Primary completion:** 2027-01
- **Final completion:** 2028-04
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04662255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04662255, "Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04662255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*